These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24681980)

  • 21. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
    Lu C; Zhou Q; Yan J; Du Z; Huang L; Li X
    Eur J Med Chem; 2013 Apr; 62():745-53. PubMed ID: 23454517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study.
    Shaikh S; Rizvi SM; Suhail T; Shakil S; Abuzenadah AM; Anis R; Naaz D; Dallol A; Haneef M; Ahmad A; Choudhary L
    CNS Neurol Disord Drug Targets; 2016; 15(10):1216-1221. PubMed ID: 27697060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potency prediction of β-secretase (BACE-1) inhibitors using density functional methods.
    Roos K; Viklund J; Meuller J; Kaspersson K; Svensson M
    J Chem Inf Model; 2014 Mar; 54(3):818-25. PubMed ID: 24456077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model.
    Tsuchida K; Chaki H; Takakura T; Kotsubo H; Tanaka T; Aikawa Y; Shiozawa S; Hirono S
    J Med Chem; 2006 Jan; 49(1):80-91. PubMed ID: 16392794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
    Kumar A; Srivastava G; Sharma A
    Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of Curcumin and Flavonoid Derivatives with Acetylcholinesterase and Beta-Secretase Inhibitory Activities Using in Silico Approaches.
    Tran TS; Le MT; Tran TD; Tran TH; Thai KM
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32785161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors.
    Li H; Xu R; Cole D; Clader JW; Greenlee WJ; Nomeir AA; Song L; Zhang L
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6606-9. PubMed ID: 20933414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids.
    Pérez-Areales FJ; Betari N; Viayna A; Pont C; Espargaró A; Bartolini M; De Simone A; Rinaldi Alvarenga JF; Pérez B; Sabate R; Lamuela-Raventós RM; Andrisano V; Luque FJ; Muñoz-Torrero D
    Future Med Chem; 2017 Jun; 9(10):965-981. PubMed ID: 28632395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
    Montanari S; Scalvini L; Bartolini M; Belluti F; Gobbi S; Andrisano V; Ligresti A; Di Marzo V; Rivara S; Mor M; Bisi A; Rampa A
    J Med Chem; 2016 Jul; 59(13):6387-406. PubMed ID: 27309570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
    Thompson LA; Liauw AY; Ramanjulu MM; Kasireddy-Polam P; Mercer SE; Maduskuie TP; Glicksman M; Roach AH; Meredith JE; Liu RQ; Combs AP; Higaki JN; Cordell B; Seiffert D; Zaczek RC; Robertson DW; Olson RE
    Bioorg Med Chem Lett; 2006 May; 16(9):2357-63. PubMed ID: 16473009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors.
    Di Martino RM; De Simone A; Andrisano V; Bisignano P; Bisi A; Gobbi S; Rampa A; Fato R; Bergamini C; Perez DI; Martinez A; Bottegoni G; Cavalli A; Belluti F
    J Med Chem; 2016 Jan; 59(2):531-44. PubMed ID: 26696252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic insights into mode of action of potent natural antagonists of BACE-1 for checking Alzheimer's plaque pathology.
    Dhanjal JK; Goyal S; Sharma S; Hamid R; Grover A
    Biochem Biophys Res Commun; 2014 Jan; 443(3):1054-9. PubMed ID: 24365147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress toward a practical BACE-1 inhibitor.
    Hills ID; Vacca JP
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):383-91. PubMed ID: 17659479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS).
    Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J
    ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.
    Linning P; Haussmann U; Beyer I; Weidlich S; Schieb H; Wiltfang J; Klafki HW; Knölker HJ
    Org Biomol Chem; 2012 Oct; 10(41):8216-35. PubMed ID: 22930158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
    Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
    Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
    Thompson LA; Shi J; Decicco CP; Tebben AJ; Olson RE; Boy KM; Guernon JM; Good AC; Liauw A; Zheng C; Copeland RA; Combs AP; Trainor GL; Camac DM; Muckelbauer JK; Lentz KA; Grace JE; Burton CR; Toyn JH; Barten DM; Marcinkeviciene J; Meredith JE; Albright CF; Macor JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6909-15. PubMed ID: 21974952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.